TiumBio Co., Ltd.
June 16, 2025
Company Presentation
Reproductive/Sexual Health
TiumBio is a South Korea-based biopharma company focused on discovering and developing innovative small molecules and biologics for serious and rare diseases. Our pipeline includes clinical and preclinical programs with first- or best-in-class potential in immuno-oncology, women’s health (endometriosis, uterine fibroids), hemophilia, and respiratory diseases. Our lead asset, TU2670 (Merigolix), is an oral GnRH antagonist that completed Phase 2a trials for endometriosis in the EU and uterine fibroids in South Korea, now advancing to the next phase. Founded in 2016, TiumBio is listed on KOSDAQ and operates with the agility of a biotech startup. Our experienced team has a strong track record in innovative drug development for both local and global markets. We are dedicated to delivering meaningful therapies to patients with high unmet medical needs.
Company HQ City:
Seongnam-si
Company HQ State:
Gyeonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2016
Lead Product in Development:
merigolix
CEO
Hun-Taek, Kim
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
Exchange
KOSDAQ
Ticker
321550
When you expect your next catalyst update?
Clinical data package for Merigolix (TU2670) ready to support partnering discussions and advancement into next-phase trials. Additional catalysts include the advancement of our immuno-oncology asset TU2218 and hemophilia program TU7710.
What is your next catalyst (value inflection) update?
H1 2025 – Completion of clinical data package for Merigolix (TU2670) to support global partnering and advancement to Phase 2b/3. Additional updates expected in H2 2025 for TU2218 (Phase 2 immuno-oncology trial) and TU7710 (Phase 1b hemophilia study in Europe).
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}